Cardiovascular Devices Market by Product (Cardiac Imaging, Rhythm Management, Cardiac Assist Devices, Interventional Cardiology, Electrophysiology, Monitoring ), Indication (CAD, MI, CHF), End User (Hospitals & Clinics) - Global Forecast to 2029

A1 INTRODUCTION 34 1.1 STUDY OBJECTIVES 34 1.2 MARKET DEFINITION 34 1.3 MARKET SCOPE 35 1.3.1 MARKET SEGMENTATION 35 1.3.2 INCLUSIONS & EXCLUSIONS 36 1.3.3 YEARS CONSIDERED 36 1.3.4 CURRENCY CONSIDERED 37 1.4 STAKEHOLDERS 37 2 RESEARCH METHODOLOGY 38 2.1 RESEARCH DATA 38 2.1.1 SECONDARY DATA 39 2.1.1.1 Key data from secondary sources 40 2.1.2 PRIMARY DATA 40 2.1.2.1 Key data from primary sources 42 2.1.2.2 Key industry insights 42 2.2 MARKET SIZE ESTIMATION 43 2.3 GROWTH FORECAST 45 2.4 MARKET BREAKDOWN & DATA TRIANGULATION 48 2.5 MARKET RANKING ANALYSIS 49 2.6 STUDY ASSUMPTIONS 49 2.7 RESEARCH LIMITATIONS 49 2.7.1 METHODOLOGY-RELATED LIMITATIONS 49 2.7.2 SCOPE-RELATED LIMITATIONS 50 2.8 RISK ASSESSMENT 50 3 EXECUTIVE SUMMARY 51 4 PREMIUM INSIGHTS 55 4.1 CARDIOVASCULAR DEVICES MARKET OVERVIEW 55 4.2 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY END USER AND COUNTRY (2023) 56 4.3 CARDIOVASCULAR DEVICES MARKET: REGIONAL MIX, 2024–2029 (USD MILLION) 57 5 MARKET OVERVIEW 58 5.1 INTRODUCTION 58 5.2 MARKET DYNAMICS 58 5.2.1 DRIVERS 59 5.2.1.1 Rising incidence of cardiovascular diseases 59 5.2.1.2 Increasing accessibility to advanced high-performance devices 59 5.2.1.3 Growing preference for minimally invasive surgeries 60 5.2.1.4 Rising technological advancements in cardiovascular devices 60 5.2.1.5 Increasing trend of remote patient monitoring 60 5.2.2 RESTRAINTS 61 5.2.2.1 Stringent regulatory guidelines for product approval 61 5.2.2.2 Shortage of skilled cardiac health professionals 62 5.2.3 OPPORTUNITIES 62 5.2.3.1 Rising geriatric population and increasing uptake of CVD devices 62 5.2.3.2 Emergence of biodegradable cardiovascular devices 62 5.2.4 CHALLENGES 63 5.2.4.1 Product recalls & failures 63 5.2.4.2 Complications associated with implantable devices 63 5.3 INDUSTRY TRENDS 64 5.3.1 MINIMALLY INVASIVE PROCEDURES 65 5.3.2 WEARABLE TECHNOLOGY AND REMOTE MONITORING 65 5.3.3 PERSONALIZED MEDICINE 65 5.4 TECHNOLOGY ANALYSIS 66 5.4.1 KEY TECHNOLOGIES 66 5.4.1.1 Transcatheter aortic valve replacement (TAVR) 66 5.4.1.2 Cardiac mapping systems 66 5.4.1.3 3D-printed cardiovascular devices 67 5.4.2 COMPLEMENTARY TECHNOLOGIES 67 5.4.2.1 Robotic-assisted surgeries 67 5.4.2.2 Advanced catheter systems 67 5.4.2.3 Imaging technologies 68 5.4.3 ADJACENT TECHNOLOGIES 68 5.4.3.1 Regenerative medicine 68 5.4.3.2 Biomaterials & nanotechnology 68 5.4.3.3 Big data & cloud computing 69 5.5 PORTER’S FIVE FORCE ANALYSIS 69 5.5.1 THREAT OF NEW ENTRANTS 69 5.5.2 BARGAINING POWER OF SUPPLIERS 70 5.5.3 BARGAINING POWER OF BUYERS 70 5.5.4 THREAT OF SUBSTITUTES 70 5.5.5 INTENSITY OF COMPETITIVE RIVALRY 70 5.6 REGULATORY LANDSCAPE 71 5.6.1 REGULATORY ANALYSIS 71 5.6.1.1 North America 71 5.6.1.1.1 US 71 5.6.1.1.2 Canada 72 5.6.1.2 Europe 72 5.6.1.3 Asia Pacific 72 5.6.1.4 Latin America 73 5.6.1.5 Middle East & Africa 73 5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74 5.7 PATENT ANALYSIS 76 5.7.1 PATENT PUBLICATION TRENDS IN CARDIOVASCULAR DEVICES MARKET 76 5.7.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 77 5.8 TRADE ANALYSIS 80 5.9 PRICING ANALYSIS 80 5.10 KEY CONFERENCES & EVENTS, 2024−2025 82 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 83 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 83 5.11.2 BUYING CRITERIA 84 5.12 UNMET NEEDS/END-USER EXPECTATIONS IN CARDIOVASCULAR DEVICES MARKET 85 5.13 IMPACT OF AI/GENERATIVE AI ON CARDIOVASCULAR DEVICES MARKET 86 5.14 ECOSYSTEM ANALYSIS 86 5.15 CASE STUDY ANALYSIS 88 5.15.1 CASE STUDY 1: EVALUATION OF TAVR SYSTEM 88 5.15.2 CASE STUDY 2: SAFETY & EFFICACY ASSESSMENT OF WATCHMAN DEVICE IN ATRIAL FIBRILLATION 89 5.15.3 CASE STUDY 3: PERFORMANCE ANALYSIS OF MITRACLIP FOR THE TREATMENT OF MITRAL REGURGITATION 90 5.16 SUPPLY CHAIN ANALYSIS 90 5.17 ADJACENT MARKET ANALYSIS 92 5.17.1 CARDIAC MONITORING AND RHYTHM MANAGEMENT DEVICES MARKET 92 5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 93 5.19 CARDIOVASCULAR DEVICES MARKET: INVESTMENT & FUNDING SCENARIO 94 5.20 R&D PIPELINE ANALYSIS 95 6 CARDIOVASCULAR DEVICES MARKET, BY PRODUCT 96 6.1 INTRODUCTION 97 6.2 CARDIAC IMAGING & DIAGNOSTIC DEVICES 98 6.2.1 ECG DEVICES 100 6.2.1.1 Low costs and expanding applications to fuel market 100 6.2.2 CARDIAC ULTRASOUND IMAGING 101 6.2.2.1 Growing preference towards minimally invasive techniques to boost demand 101 6.2.3 CARDIAC COMPUTERIZED TOMOGRAPHY (CT) SCANNERS 103 6.2.3.1 Increasing preference over other diagnostic imaging methods to drive market 103   6.2.4 CARDIAC MAGNETIC RESONANCE IMAGING (MRI) 104 6.2.4.1 Increasing incidence of cardiac diseases to fuel uptake 104 6.2.5 NUCLEAR CARDIOLOGY SYSTEMS 106 6.2.5.1 Ability to assess tissue functionality and heart physiology to support market growth 106 6.2.6 CARDIAC DIAGNOSTIC CATHETERS 107 6.2.6.1 Rising focus on catheterization procedures to fuel market 107 6.3 CARDIAC RHYTHM MANAGEMENT DEVICES 109 6.3.1 PACEMAKERS 111 6.3.1.1 Growing availability of leadless and MRI-safe devices to boost demand 111 6.3.2 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD) 112 6.3.2.1 Increasing prevalence of arrhythmias to drive market 112 6.3.3 CARDIAC RESYNCHRONIZATION THERAPY (CRT) DEVICES 114 6.3.3.1 Ability to reduce fatigue and associated heart failure symptoms to boost demand 114 6.4 INTERVENTIONAL CARDIOLOGY DEVICES 115 6.4.1 CORONARY STENTS 118 6.4.1.1 Technological advancements in stents to fuel uptake 118 6.4.2 HEART VALVE DEVICES 120 6.4.2.1 Increasing prevalence of valve stenosis and regurgitation to fuel market 120 6.4.3 CLOSURE DEVICES 121 6.4.3.1 Utilization of self-expandable materials to drive market 121 6.4.4 SURGICAL CATHETERS 122 6.4.4.1 Rising adoption of angioplasty procedures to support market growth 122 6.4.5 GUIDEWIRES 124 6.4.5.1 Rising uptake in PCI procedures to drive market 124 6.4.6 OTHER INTERVENTIONAL CARDIOLOGY DEVICES 125 6.5 CARDIAC ASSIST DEVICES 127 6.5.1 VENTRICULAR ASSIST DEVICES 129 6.5.1.1 Rising incidence of heart failure to boost market 129 6.5.2 INTRA-AORTIC BALLOON PUMPS (IABP) 130 6.5.2.1 Product recalls to restrain market 130 6.5.3 TOTAL ARTIFICIAL HEART (TAH) 131 6.5.3.1 Growing product pipeline to fuel market 131 6.5.4 IMPELLA DEVICES 133 6.5.4.1 Increasing utility in high-risk procedures to support market growth 133 6.6 ELECTROPHYSIOLOGY DEVICES 134 6.6.1 EP CATHETERS 136 6.6.1.1 Rising incidence of chronic heart conditions to drive market 136   6.6.2 ABLATION SYSTEMS 137 6.6.2.1 Increasing utilization of radiofrequency ablation procedures to support market growth 137 6.6.3 3D MAPPING SYSTEM 139 6.6.3.1 Development of alternative technologies to hinder market 139 6.7 EXTERNAL SUPPORT DEVICES 140 6.7.1 EXTERNAL DEFIBRILLATORS 142 6.7.1.1 Adoption of user-friendly AEDs to fuel market 142 6.7.2 EXTERNAL PACEMAKERS 143 6.7.2.1 Technological advancements in leadless & implantable pacemakers to restrain market 143 6.7.3 CARDIAC COMPRESSION DEVICES 145 6.7.3.1 Reduced CPR rate to restrain market 145 6.8 MONITORING DEVICES 146 6.8.1 BLOOD PRESSURE MONITORS 148 6.8.1.1 Portability and ease of use to fuel market 148 6.8.2 PULSE OXIMETERS 149 6.8.2.1 Increasing adoption of OTC devices in home care settings to propel market 149 6.8.3 IMPLANTABLE CARDIAC MONITORS (ICM) 151 6.8.3.1 Growing focus on RPM to support market 151 7 CARDIOVASCULAR DEVICES MARKET, BY INDICATION 153 7.1 INTRODUCTION 154 7.2 CORONARY ARTERY DISEASE 155 7.2.1 ANGINA PECTORIS 156 7.2.1.1 Growing adoption of implantable monitors and ECG devices for treatment to drive market 156 7.2.2 MYOCARDIAL INFARCTION 158 7.2.2.1 Increasing demand for stents in acute cases to fuel market 158 7.3 ARRHYTHMIAS 159 7.3.1 TACHYCARDIA 161 7.3.1.1 Rising cardiac electrophysiology procedures to drive market 161 7.3.2 BRADYCARDIA 162 7.3.2.1 Rising incidence of OSA to support market growth 162 7.4 STRUCTURAL HEART DISEASE 164 7.4.1 VALVULAR HEART DISEASE 165 7.4.1.1 Rising risks of aortic stenosis to drive market 165 7.4.2 CONGENITAL HEART DISEASE 167 7.4.2.1 Potential for new therapies to fuel uptake 167 7.4.3 CARDIOMYOPATHY 168 7.4.3.1 Uptake of ICDs to drive market 168   7.4.4 CONGESTIVE HEART FAILURE 170 7.4.4.1 Growth in geriatric population to fuel market 170 7.5 INFLAMMATORY HEART DISEASE 171 7.5.1 PERICARDITIS 173 7.5.1.1 Increasing incidence due to COVID-19 to support market growth 173 7.5.2 MYOCARDITIS 175 7.5.2.1 Increasing prevalence of autoimmune diseases to support market growth 175 7.5.3 ENDOCARDITIS 176 7.5.3.1 Focus on echocardiography for clinical evaluation to drive market 176 7.6 OTHER CARDIOVASCULAR INDICATIONS 178 8 CARDIOVASCULAR DEVICES MARKET, BY END USER 180 8.1 INTRODUCTION 181 8.2 HOSPITALS & CLINCS 182 8.2.1 HIGH PURCHASING POWER OF HOSPITALS AND RISING NUMBER OF CARDIOVASCULAR PROCEDURES TO DRIVE MARKET 182 8.3 DIAGNOSTIC LABORATORIES 184 8.3.1 RISING FOCUS ON TECHNOLOGICALLY ADVANCED DIAGNOSTIC INSTRUMENTS TO SUPPORT MARKET GROWTH 184 8.4 AMBULATORY SURGERY CENTERS 185 8.4.1 INCREASING DEMAND FOR OUTPATIENT CARE AND RPM SERVICES TO PROPEL MARKET 185 8.5 OTHER END USERS 187 9 CARDIOVASCULAR DEVICES MARKET, BY REGION 189 9.1 INTRODUCTION 190 9.2 NORTH AMERICA 191 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 191 9.2.2 US 205 9.2.2.1 Increasing cases of obesity due to sedentary lifestyles to propel market 205 9.2.3 CANADA 216 9.2.3.1 Increasing funding for CVD research to support market growth 216 9.3 EUROPE 227 9.3.1 INCREASING PRODUCT APPROVALS FOR ADVANCED CARDIOVASCULAR DEVICES TO DRIVE MARKET 227 9.3.2 MACROECONOMIC OUTLOOK FOR EUROPE 227 9.4 ASIA PACIFIC 240 9.4.1 LARGE TARGET PATIENT POPULATION AND INCREASING INCIDENCE OF CVD TO PROPEL MARKET 240 9.4.2 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 240   9.5 LATIN AMERICA 252 9.5.1 BURDEN OF CONGENITAL HEART DISEASES TO DRIVE MARKET 252 9.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 253 9.6 MIDDLE EAST & AFRICA 265 9.6.1 RISING HEALTHCARE EXPENDITURE TO SUPPORT MARKET GROWTH 265 9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 265 10 COMPETITIVE LANDSCAPE 279 10.1 OVERVIEW 279 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 279 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CARDIOVASCULAR DEVICES MARKET 280 10.3 REVENUE ANALYSIS 282 10.4 MARKET SHARE ANALYSIS 283 10.4.1 RANKING OF KEY MARKET PLAYERS, 2023 285 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 285 10.5.1 STARS 285 10.5.2 EMERGING LEADERS 285 10.5.3 PERVASIVE PLAYERS 286 10.5.4 PARTICIPANTS 286 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 287 10.5.5.1 Company footprint 287 10.5.5.2 Region footprint 288 10.5.5.3 Product footprint 289 10.5.5.4 Indication footprint 290 10.5.5.5 End-user footprint 291 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 292 10.6.1 PROGRESSIVE COMPANIES 292 10.6.2 RESPONSIVE COMPANIES 292 10.6.3 DYNAMIC COMPANIES 292 10.6.4 STARTING BLOCKS 292 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 294 10.7 COMPANY VALUATION & FINANCIAL METRICS 295 10.7.1 COMPANY VALUATION 295 10.7.2 FINANCIAL METRICS 296 10.8 BRAND/PRODUCT COMPARISON 296 10.9 COMPETITIVE SCENARIO 297 10.9.1 PRODUCT LAUNCHES & APPROVALS 297 10.9.2 DEALS 298 10.9.3 EXPANSIONS 299 10.9.4 OTHER DEVELOPMENTS 299   11 COMPANY PROFILES 300 11.1 KEY PLAYERS 300 11.1.1 MEDTRONIC 300 11.1.1.1 Business overview 300 11.1.1.2 Products offered 301 11.1.1.3 Recent developments 309 11.1.1.3.1 Product launches & approvals 309 11.1.1.3.2 Deals 310 11.1.1.4 MnM view 311 11.1.1.4.1 Key strengths 311 11.1.1.4.2 Strategic choices 311 11.1.1.4.3 Weaknesses & competitive threats 311 11.1.2 ABBOTT LABORATORIES 312 11.1.2.1 Business overview 312 11.1.2.2 Products offered 313 11.1.2.3 Recent developments 321 11.1.2.3.1 Product launches & approvals 321 11.1.2.3.2 Deals 323 11.1.2.4 MnM view 323 11.1.2.4.1 Key strengths 323 11.1.2.4.2 Strategic choices 324 11.1.2.4.3 Weaknesses & competitive threats 324 11.1.3 BOSTON SCIENTIFIC CORPORATION 325 11.1.3.1 Business overview 325 11.1.3.2 Products offered 326 11.1.3.3 Recent developments 333 11.1.3.3.1 Product launches & approvals 333 11.1.3.3.2 Deals 333 11.1.3.4 MnM view 335 11.1.3.4.1 Key strengths 335 11.1.3.4.2 Strategic choices 335 11.1.3.4.3 Weaknesses & competitive threats 335 11.1.4 GE HEALTHCARE 336 11.1.4.1 Business overview 336 11.1.4.2 Products offered 337 11.1.4.3 Recent developments 339 11.1.4.3.1 Product launches & approvals 339 11.1.4.3.2 Deals 340 11.1.4.4 MnM view 341 11.1.4.4.1 Key strengths 341 11.1.4.4.2 Strategic choices 341 11.1.4.4.3 Weaknesses & competitive threats 341 11.1.5 TERUMO CORPORATION 342 11.1.5.1 Business overview 342 11.1.5.2 Products offered 343 11.1.5.3 Recent developments 347 11.1.5.3.1 Product launches & approvals 347 11.1.5.4 MnM view 348 11.1.5.4.1 Key strengths 348 11.1.5.4.2 Strategic choices 348 11.1.5.4.3 Weaknesses & competitive threats 348 11.1.6 EDWARDS LIFESCIENCES CORPORATION 349 11.1.6.1 Business overview 349 11.1.6.2 Products offered 350 11.1.6.3 Recent developments 352 11.1.6.3.1 Product launches & approvals 352 11.1.6.3.2 Deals 353 11.1.7 SIEMENS HEALTHINEERS AG 354 11.1.7.1 Business overview 354 11.1.7.2 Products offered 355 11.1.7.3 Recent developments 357 11.1.7.3.1 Product launches & approvals 357 11.1.8 JOHNSON AND JOHNSON SERVICES, INC. 358 11.1.8.1 Business overview 358 11.1.8.2 Products offered 359 11.1.8.3 Recent developments 362 11.1.8.3.1 Product launches & approvals 362 11.1.8.3.2 Deals 363 11.1.9 SAHAJANAND MEDICAL TECHNOLOGIES LIMITED 364 11.1.9.1 Business overview 364 11.1.9.2 Products offered 364 11.1.10 BAXTER INTERNATIONAL INC 366 11.1.10.1 Business overview 366 11.1.10.2 Products offered 367 11.1.10.3 Recent developments 369 11.1.10.3.1 Deals 369 11.1.11 ARTIVION, INC. 370 11.1.11.1 Business overview 370 11.1.11.2 Products offered 371 11.1.12 GETINGE AB 373 11.1.12.1 Business overview 373 11.1.12.2 Products offered 374 11.1.12.3 Recent developments 375 11.1.12.3.1 Product launches & approvals 375 11.1.12.3.2 Deals 375 11.1.13 KONINKLIJKE PHILIPS N.V. 376 11.1.13.1 Business overview 376 11.1.13.2 Products offered 377 11.1.13.3 Recent developments 379 11.1.13.3.1 Product launches & approvals 379 11.1.14 NIHON KOHDEN CORPORATION 380 11.1.14.1 Business overview 380 11.1.14.2 Products offered 381 11.1.15 BIOTRONIK SE & CO.KG. 383 11.1.15.1 Business overview 383 11.1.15.2 Products offered 383 11.1.16 LEPU MEDICAL TECHNOLOGY(BEIJING) CO., LTD. 388 11.1.16.1 Business overview 388 11.1.16.2 Products offered 388 11.1.16.3 Recent developments 394 11.1.16.3.1 Product launches & approvals 394 11.1.17 MICROPORT SCIENTIFIC CORPORATION 396 11.1.17.1 Business overview 396 11.1.17.2 Products offered 397 11.1.17.3 Recent developments 401 11.1.17.3.1 Product launches & approvals 401 11.1.18 ANGIODYNAMICS INC. 403 11.1.18.1 Business overview 403 11.1.18.2 Products offered 405 11.1.19 JAPAN LIFELINE CO., LTD. 406 11.1.19.1 Business overview 406 11.1.19.2 Products offered 407 11.1.19.3 Recent developments 410 11.1.19.3.1 Product launches & approvals 410 11.1.20 W.L. GORE & ASSOCIATES 411 11.1.20.1 Business overview 411 11.1.20.2 Products offered 411 11.1.21 B. BRAUN SE 412 11.1.21.1 Business overview 412 11.1.21.2 Products offered 414 11.2 OTHER PLAYERS 415 11.2.1 CANON MEDICAL SYSTEMS CORPORATION 415 11.2.2 PICARD MEDICAL COMPANY 416 11.2.3 BPL MEDICAL TECHNOLOGIES PVT LTD 417 11.2.4 LIFETECH SCIENTIFIC CORPORATION 418 11.2.5 ORBUSNEICH MEDICAL GROUP HOLDINGS LIMITED 419 12 APPENDIX 420 12.1 DISCUSSION GUIDE 420 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 425 12.3 CUSTOMIZATION OPTIONS 427 12.4 RELATED REPORTS 427 12.5 AUTHOR DETAILS 428

TABLE 1 CURRENCY CONVERSION RATES 37 TABLE 2 CARDIOVASCULAR DEVICES MARKET: STUDY ASSUMPTIONS 49 TABLE 3 CARDIOVASCULAR DEVICES MARKET: RISK ASSESSMENT ANALYSIS 50 TABLE 4 POTENTIAL ADVERSE EFFECTS ASSOCIATED WITH DIFFERENT DEVICES 64 TABLE 5 PORTER’S FIVE FORCES ANALYSIS 69 TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74 TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74 TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75 TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75 TABLE 10 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76 TABLE 11 LIST OF PATENTS IN CARDIOVASCULAR DEVICES MARKET, 2014−2024 79 TABLE 12 IMPORT DATA FOR CARDIOVASCULAR DEVICES MARKET, BY COUNTRY, 2018–2023 (USD MILLION) 80 TABLE 13 EXPORT DATA FOR CARDIOVASCULAR DEVICES, BY COUNTRY, 2018–2023 (USD MILLION) 80 TABLE 14 CARDIOVASCULAR DEVICES MARKET: AVERAGE SELLING PRICE, BY PRODUCT (2023) 81 TABLE 15 AVERAGE SELLING PRICE TREND OF CARDIOVASCULAR DEVICES, BY REGION (2023) 81 TABLE 16 CARDIOVASCULAR DEVICES MARKET: KEY CONFERENCES & EVENTS, 2024−2025 82 TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 END USERS 83 TABLE 18 KEY BUYING CRITERIA FOR TOP 3 END USERS OF CARDIOVASCULAR DEVICES 84 TABLE 19 CARDIOVASCULAR DEVICES MARKET: UNMET NEEDS 85 TABLE 20 CARDIOVASCULAR DEVICES MARKET: END-USER EXPECTATIONS 85 TABLE 21 CARDIOVASCULAR DEVICES MARKET: IMPACT OF AI/GENERATIVE AI 86 TABLE 22 CARDIOVASCULAR DEVICES MARKET: ECOSYSTEM ANALYSIS 87 TABLE 23 CARDIOVASCULAR DEVICES MARKET: R&D PIPELINE ANALYSIS 95 TABLE 24 CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2021–2023 (USD MILLION) 97 TABLE 25 CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024–2029 (USD MILLION) 97 TABLE 26 CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 98 TABLE 27 CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 98 TABLE 28 CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 99 TABLE 29 CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 99 TABLE 30 ECG DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 101 TABLE 31 ECG DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 101 TABLE 32 CARDIAC ULTRASOUND IMAGING MARKET, BY REGION, 2021–2023 (USD MILLION) 102 TABLE 33 CARDIAC ULTRASOUND IMAGING MARKET, BY REGION, 2024–2029 (USD MILLION) 103 TABLE 34 CARDIAC CT SCANNERS MARKET, BY REGION, 2021–2023 (USD MILLION) 104 TABLE 35 CARDIAC CT SCANNERS MARKET, BY REGION, 2024–2029 (USD MILLION) 104 TABLE 36 CARDIAC MRI MARKET, BY REGION, 2021–2023 (USD MILLION) 105 TABLE 37 CARDIAC MRI MARKET, BY REGION, 2024–2029 (USD MILLION) 106 TABLE 38 NUCLEAR CARDIOLOGY SYSTEMS MARKET, BY REGION, 2021–2023 (USD MILLION) 107 TABLE 39 NUCLEAR CARDIOLOGY SYSTEMS MARKET, BY REGION, 2024–2029 (USD MILLION) 107 TABLE 40 CARDIAC DIAGNOSTIC CATHETERS MARKET, BY REGION, 2021–2023 (USD MILLION) 108 TABLE 41 CARDIAC DIAGNOSTIC CATHETERS MARKET, BY REGION, 2024–2029 (USD MILLION) 108 TABLE 42 CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 109 TABLE 43 CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 109 TABLE 44 CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 110 TABLE 45 CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 110 TABLE 46 CARDIOVASCULAR DEVICES MARKET: LIST OF COMPANIES WITH KEY PRODUCTS 111 TABLE 47 PACEMAKERS MARKET, BY REGION, 2021–2023 (USD MILLION) 112 TABLE 48 PACEMAKERS MARKET, BY REGION, 2024–2029 (USD MILLION) 112 TABLE 49 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET, BY REGION, 2021–2023 (USD MILLION) 113 TABLE 50 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET, BY REGION, 2024–2029 (USD MILLION) 114 TABLE 51 CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 115 TABLE 52 CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 115 TABLE 53 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 116 TABLE 54 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 116 TABLE 55 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 117 TABLE 56 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 117 TABLE 57 CORONARY STENTS MARKET, BY REGION, 2021–2023 (USD MILLION) 119 TABLE 58 CORONARY STENTS MARKET, BY REGION, 2024–2029 (USD MILLION) 119 TABLE 59 HEART VALVE DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 120 TABLE 60 HEART VALVE DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 121 TABLE 61 CLOSURE DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 122 TABLE 62 CLOSURE DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 122 TABLE 63 SURGICAL CATHETERS MARKET, BY REGION, 2021–2023 (USD MILLION) 123 TABLE 64 SURGICAL CATHETERS MARKET, BY REGION, 2024–2029 (USD MILLION) 123 TABLE 65 GUIDEWIRES MARKET, BY REGION, 2021–2023 (USD MILLION) 124 TABLE 66 GUIDEWIRES MARKET, BY REGION, 2024–2029 (USD MILLION) 125 TABLE 67 OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 126 TABLE 68 OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 126 TABLE 69 CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 127 TABLE 70 CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 127 TABLE 71 CARDIAC ASSIST DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 128 TABLE 72 CARDIAC ASSIST DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 128 TABLE 73 VENTRICULAR ASSIST DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 129 TABLE 74 VENTRICULAR ASSIST DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 130 TABLE 75 INTRA-AORTIC BALLOON PUMPS MARKET, BY REGION, 2021–2023 (USD MILLION) 131 TABLE 76 INTRA-AORTIC BALLOON PUMPS MARKET, BY REGION, 2024–2029 (USD MILLION) 131 TABLE 77 TOTAL ARTIFICIAL HEART MARKET, BY REGION, 2021–2023 (USD MILLION) 132 TABLE 78 TOTAL ARTIFICIAL HEART MARKET, BY REGION, 2024–2029 (USD MILLION) 132 TABLE 79 IMPELLA DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 133 TABLE 80 IMPELLA DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 134 TABLE 81 ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 134 TABLE 82 ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 135 TABLE 83 ELECTROPHYSIOLOGY DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 135 TABLE 84 ELECTROPHYSIOLOGY DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 136 TABLE 85 EP CATHETERS MARKET, BY REGION, 2021–2023 (USD MILLION) 137 TABLE 86 EP CATHETERS MARKET, BY REGION, 2024–2029 (USD MILLION) 137 TABLE 87 ABLATION SYSTEMS MARKET, BY REGION, 2021–2023 (USD MILLION) 138 TABLE 88 ABLATION SYSTEMS MARKET, BY REGION, 2024–2029 (USD MILLION) 138 TABLE 89 3D MAPPING SYSTEMS MARKET, BY REGION, 2021–2023 (USD MILLION) 139 TABLE 90 3D MAPPING SYSTEMS MARKET, BY REGION, 2024–2029 (USD MILLION) 140 TABLE 91 EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 140 TABLE 92 EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 141 TABLE 93 EXTERNAL SUPPORT DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 141 TABLE 94 EXTERNAL SUPPORT DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 142 TABLE 95 EXTERNAL DEFIBRILLATORS MARKET, BY REGION, 2021–2023 (USD MILLION) 143 TABLE 96 EXTERNAL DEFIBRILLATORS MARKET, BY REGION, 2024–2029 (USD MILLION) 143 TABLE 97 EXTERNAL PACEMAKERS MARKET, BY REGION, 2021–2023 (USD MILLION) 144 TABLE 98 EXTERNAL PACEMAKERS MARKET, BY REGION, 2024–2029 (USD MILLION) 145 TABLE 99 CARDIAC COMPRESSION DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 146 TABLE 100 CARDIAC COMPRESSION DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 146 TABLE 101 CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 147 TABLE 102 CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 147 TABLE 103 CARDIOVASCULAR MONITORING DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 147 TABLE 104 CARDIOVASCULAR MONITORING DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 148 TABLE 105 BLOOD PRESSURE MONITORS MARKET, BY REGION, 2021–2023 (USD MILLION) 149 TABLE 106 BLOOD PRESSURE MONITORS MARKET, BY REGION, 2024–2029 (USD MILLION) 149 TABLE 107 PULSE OXIMETERS MARKET, BY REGION, 2021–2023 (USD MILLION) 150 TABLE 108 PULSE OXIMETERS MARKET, BY REGION, 2024–2029 (USD MILLION) 150 TABLE 109 IMPLANTABLE CARDIAC MONITORS MARKET, BY REGION, 2021–2023 (USD MILLION) 151 TABLE 110 IMPLANTABLE CARDIAC MONITORS MARKET, BY REGION, 2024–2029 (USD MILLION) 152 TABLE 111 CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2021–2023 (USD MILLION) 154 TABLE 112 CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024–2029 (USD MILLION) 154 TABLE 113 CORONARY ARTERY DISEASE MARKET, BY TYPE, 2021–2023 (USD MILLION) 155 TABLE 114 CORONARY ARTERY DISEASE MARKET, BY TYPE, 2024–2029 (USD MILLION) 155 TABLE 115 CORONARY ARTERY DISEASE MARKET, BY REGION, 2021–2023 (USD MILLION) 156 TABLE 116 CORONARY ARTERY DISEASE MARKET, BY REGION, 2024–2029 (USD MILLION) 156 TABLE 117 CORONARY ARTERY DISEASE MARKET FOR ANGINA PECTORIS, BY REGION, 2021–2023 (USD MILLION) 157 TABLE 118 CORONARY ARTERY DISEASE MARKET FOR ANGINA PECTORIS, BY REGION, 2024–2029 (USD MILLION) 157 TABLE 119 CORONARY ARTERY DISEASE MARKET FOR MYOCARDIAL INFRACTION, BY REGION, 2021–2023 (USD MILLION) 158 TABLE 120 CORONARY ARTERY DISEASE MARKET FOR MYOCARDIAL INFRACTION, BY REGION, 2024–2029 (USD MILLION) 159 TABLE 121 ARRHYTHMIAS MARKET, BY TYPE, 2021–2023 (USD MILLION) 159 TABLE 122 ARRHYTHMIAS MARKET, BY TYPE, 2024–2029 (USD MILLION) 160 TABLE 123 ARRHYTHMIAS MARKET, BY REGION, 2021–2023 (USD MILLION) 160 TABLE 124 ARRHYTHMIAS MARKET, BY REGION, 2024–2029 (USD MILLION) 160 TABLE 125 ARRHYTHMIAS MARKET FOR TACHYCARDIA, BY REGION, 2021–2023 (USD MILLION) 161 TABLE 126 ARRHYTHMIAS MARKET FOR TACHYCARDIA, BY REGION, 2024–2029 (USD MILLION) 162 TABLE 127 ARRHYTHMIAS MARKET FOR BRADYCARDIA, BY REGION, 2021–2023 (USD MILLION) 163 TABLE 128 ARRHYTHMIAS MARKET FOR BRADYCARDIA, BY REGION, 2024–2029 (USD MILLION) 163 TABLE 129 STRUCTURAL HEART DISEASE MARKET, BY TYPE, 2021–2023 (USD MILLION) 164 TABLE 130 STRUCTURAL HEART DISEASE MARKET, BY TYPE, 2024–2029 (USD MILLION) 164 TABLE 131 STRUCTURAL HEART DISEASE MARKET, BY REGION, 2021–2023 (USD MILLION) 165 TABLE 132 STRUCTURAL HEART DISEASE MARKET, BY REGION, 2024–2029 (USD MILLION) 165 TABLE 133 VALVULAR HEART DISEASE MARKET, BY REGION, 2021–2023 (USD MILLION) 166 TABLE 134 VALVULAR HEART DISEASE MARKET, BY REGION, 2024–2029 (USD MILLION) 167 TABLE 135 CONGENITAL HEART DISEASE MARKET, BY REGION, 2021–2023 (USD MILLION) 168 TABLE 136 CONGENITAL HEART DISEASE MARKET, BY REGION, 2024–2029 (USD MILLION) 168 TABLE 137 CARDIOMYOPATHY MARKET, BY REGION, 2021–2023 (USD MILLION) 169 TABLE 138 CARDIOMYOPATHY MARKET, BY REGION, 2024–2029 (USD MILLION) 170 TABLE 139 CONGESTIVE HEART FAILURE MARKET, BY REGION, 2021–2023 (USD MILLION) 171 TABLE 140 CONGESTIVE HEART FAILURE MARKET, BY REGION, 2024–2029 (USD MILLION) 171 TABLE 141 INFLAMMATORY HEART DISEASE MARKET, BY TYPE, 2021–2023 (USD MILLION) 172 TABLE 142 INFLAMMATORY HEART DISEASE MARKET, BY TYPE, 2024–2029 (USD MILLION) 172 TABLE 143 INFLAMMATORY HEART DISEASE MARKET, BY REGION, 2021–2023 (USD MILLION) 172 TABLE 144 INFLAMMATORY HEART DISEASE MARKET, BY REGION, 2024–2029 (USD MILLION) 173 TABLE 145 INFLAMMATORY HEART DISEASE MARKET FOR PERICARDITIS, BY REGION, 2021–2023 (USD MILLION) 174 TABLE 146 INFLAMMATORY HEART DISEASE MARKET FOR PERICARDITIS, BY REGION, 2024–2029 (USD MILLION) 174 TABLE 147 INFLAMMATORY HEART DISEASE MARKET FOR MYOCARDITIS, BY REGION, 2021–2023 (USD MILLION) 175 TABLE 148 INFLAMMATORY HEART DISEASE MARKET FOR MYOCARDITIS, BY REGION, 2024–2029 (USD MILLION) 176 TABLE 149 INFLAMMATORY HEART DISEASE MARKET FOR ENDOCARDITIS, BY REGION, 2021–2023 (USD MILLION) 177 TABLE 150 INFLAMMATORY HEART DISEASE MARKET FOR ENDOCARDITIS, BY REGION, 2024–2029 (USD MILLION) 177 TABLE 151 OTHER CARDIOVASCULAR INDICATIONS MARKET, BY REGION, 2021–2023 (USD MILLION) 178 TABLE 152 OTHER CARDIOVASCULAR INDICATIONS MARKET, BY REGION, 2024–2029 (USD MILLION) 179 TABLE 153 CARDIOVASCULAR DEVICES MARKET, BY END USER, 2021–2023 (USD MILLION) 181 TABLE 154 CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024–2029 (USD MILLION) 181 TABLE 155 CARDIOVASCULAR DEVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021–2023 (USD MILLION) 183 TABLE 156 CARDIOVASCULAR DEVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024–2029 (USD MILLION) 183 TABLE 157 CARDIOVASCULAR DEVICES MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2023 (USD MILLION) 184 TABLE 158 CARDIOVASCULAR DEVICES MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024–2029 (USD MILLION) 185 TABLE 159 CARDIOVASCULAR DEVICES MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2021–2023 (USD MILLION) 186 TABLE 160 CARDIOVASCULAR DEVICES MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2024–2029 (USD MILLION) 186 TABLE 161 CARDIOVASCULAR DEVICES MARKET FOR OTHER END USERS, BY REGION, 2021–2023 (USD MILLION) 187 TABLE 162 CARDIOVASCULAR DEVICES MARKET FOR OTHER END USERS, BY REGION, 2024–2029 (USD MILLION) 188 TABLE 163 CARDIOVASCULAR DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 190 TABLE 164 CARDIOVASCULAR DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 191 TABLE 165 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY COUNTRY, 2021–2023 (USD MILLION) 192 TABLE 166 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY COUNTRY, 2024–2029 (USD MILLION) 193 TABLE 167 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2021–2023 (USD MILLION) 193 TABLE 168 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024–2029 (USD MILLION) 194 TABLE 169 NORTH AMERICA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 194 TABLE 170 NORTH AMERICA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 195 TABLE 171 NORTH AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 195 TABLE 172 NORTH AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 195 TABLE 173 NORTH AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021–2023 (THOUSAND UNITS) 196 TABLE 174 NORTH AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024–2029 (THOUSAND UNITS) 196 TABLE 175 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 196 TABLE 176 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 197 TABLE 177 NORTH AMERICA: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 197 TABLE 178 NORTH AMERICA: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 198 TABLE 179 NORTH AMERICA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 198 TABLE 180 NORTH AMERICA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 198 TABLE 181 NORTH AMERICA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 199 TABLE 182 NORTH AMERICA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 199 TABLE 183 NORTH AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 199 TABLE 184 NORTH AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 200 TABLE 185 NORTH AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021–2023 (THOUSAND UNITS) 200 TABLE 186 NORTH AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024–2029 (THOUSAND UNITS) 200 TABLE 187 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2021–2023 (USD MILLION) 201 TABLE 188 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024–2029 (USD MILLION) 201 TABLE 189 NORTH AMERICA: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 202 TABLE 190 NORTH AMERICA: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 202 TABLE 191 NORTH AMERICA: ARRHYTHMIAS MARKET, BY INDICATION, 2021–2023 (USD MILLION) 202 TABLE 192 NORTH AMERICA: ARRHYTHMIAS MARKET, BY INDICATION, 2024–2029 (USD MILLION) 203 TABLE 193 NORTH AMERICA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 203 TABLE 194 NORTH AMERICA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 203 TABLE 195 NORTH AMERICA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 204 TABLE 196 NORTH AMERICA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 204 TABLE 197 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2021–2023 (USD MILLION) 204 TABLE 198 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024–2029 (USD MILLION) 205 TABLE 199 US: KEY MACROINDICATORS 205 TABLE 200 US: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2021–2023 (USD MILLION) 206 TABLE 201 US: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024–2029 (USD MILLION) 206 TABLE 202 US: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 207 TABLE 203 US: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 207 TABLE 204 US: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 208 TABLE 205 US: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 208 TABLE 206 US: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 208 TABLE 207 US: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 209 TABLE 208 US: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 209 TABLE 209 US: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 209 TABLE 210 US: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 210 TABLE 211 US: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 210 TABLE 212 US: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 210 TABLE 213 US: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 211 TABLE 214 US: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 211 TABLE 215 US: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 211 TABLE 216 US: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2021–2023 (USD MILLION) 212 TABLE 217 US: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024–2029 (USD MILLION) 212 TABLE 218 US: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 212 TABLE 219 US: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 213 TABLE 220 US: ARRHYTHMIAS MARKET, BY INDICATION, 2021–2023 (USD MILLION) 213 TABLE 221 US: ARRHYTHMIAS MARKET, BY INDICATION, 2024–2029 (USD MILLION) 213 TABLE 222 US: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 214 TABLE 223 US: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 214 TABLE 224 US: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 214 TABLE 225 US: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 215 TABLE 226 US: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2021–2023 (USD MILLION) 215 TABLE 227 US: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024–2029 (USD MILLION) 215 TABLE 228 CANADA: KEY MACROINDICATORS 216 TABLE 229 CANADA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2021–2023 (USD MILLION) 216 TABLE 230 CANADA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024–2029 (USD MILLION) 217 TABLE 231 CANADA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 217 TABLE 232 CANADA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 218 TABLE 233 CANADA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 218 TABLE 234 CANADA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 218 TABLE 235 CANADA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 219 TABLE 236 CANADA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 219 TABLE 237 CANADA: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 220 TABLE 238 CANADA: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 220 TABLE 239 CANADA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 220 TABLE 240 CANADA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 221 TABLE 241 CANADA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 221 TABLE 242 CANADA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 221 TABLE 243 CANADA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 222 TABLE 244 CANADA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 222 TABLE 245 CANADA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2021–2023 (USD MILLION) 222 TABLE 246 CANADA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024–2029 (USD MILLION) 223 TABLE 247 CANADA: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 223 TABLE 248 CANADA: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 223 TABLE 249 CANADA: ARRHYTHMIAS MARKET, BY INDICATION, 2021–2023 (USD MILLION) 224 TABLE 250 CANADA: ARRHYTHMIAS MARKET, BY INDICATION, 2024–2029 (USD MILLION) 224 TABLE 251 CANADA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 224 TABLE 252 CANADA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 225 TABLE 253 CANADA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 225 TABLE 254 CANADA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 225 TABLE 255 CANADA: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2021–2023 (USD MILLION) 226 TABLE 256 CANADA: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024–2029 (USD MILLION) 226 TABLE 257 EUROPE: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2021–2023 (USD MILLION) 228 TABLE 258 EUROPE: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024–2029 (USD MILLION) 228 TABLE 259 EUROPE: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 229 TABLE 260 EUROPE: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 229 TABLE 261 EUROPE: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 230 TABLE 262 EUROPE: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 230 TABLE 263 EUROPE: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021–2023 (THOUSAND UNITS) 230 TABLE 264 EUROPE: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024–2029 (THOUSAND UNITS) 231 TABLE 265 EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 231 TABLE 266 EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 232 TABLE 267 EUROPE: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 232 TABLE 268 EUROPE: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 232 TABLE 269 EUROPE: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 233 TABLE 270 EUROPE: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 233 TABLE 271 EUROPE: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 233 TABLE 272 EUROPE: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 234 TABLE 273 EUROPE: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 234 TABLE 274 EUROPE: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 234 TABLE 275 EUROPE: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021–2023 (THOUSAND UNITS) 235 TABLE 276 EUROPE: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024–2029 (THOUSAND UNITS) 235 TABLE 277 EUROPE: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2021–2023 (USD MILLION) 235 TABLE 278 EUROPE: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024–2029 (USD MILLION) 236 TABLE 279 EUROPE: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 236 TABLE 280 EUROPE: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 236 TABLE 281 EUROPE: ARRHYTHMIAS MARKET, BY INDICATION, 2021–2023 (USD MILLION) 237 TABLE 282 EUROPE: ARRHYTHMIAS MARKET, BY INDICATION, 2024–2029 (USD MILLION) 237 TABLE 283 EUROPE: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 237 TABLE 284 EUROPE: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 238 TABLE 285 EUROPE: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 238 TABLE 286 EUROPE: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 238 TABLE 287 EUROPE: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2021–2023 (USD MILLION) 239 TABLE 288 EUROPE: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024–2029 (USD MILLION) 239 TABLE 289 ASIA PACIFIC: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2021–2023 (USD MILLION) 241 TABLE 290 ASIA PACIFIC: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024–2029 (USD MILLION) 241 TABLE 291 ASIA PACIFIC: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 242 TABLE 292 ASIA PACIFIC: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 242 TABLE 293 ASIA PACIFIC: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 243 TABLE 294 ASIA PACIFIC: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 243 TABLE 295 ASIA PACIFIC: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021–2023 (THOUSAND UNITS) 243 TABLE 296 ASIA PACIFIC: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024–2029 (THOUSAND UNITS) 244 TABLE 297 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 244 TABLE 298 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 245 TABLE 299 ASIA PACIFIC: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 245 TABLE 300 ASIA PACIFIC: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 245 TABLE 301 ASIA PACIFIC: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 246 TABLE 302 ASIA PACIFIC: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 246 TABLE 303 ASIA PACIFIC: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 246 TABLE 304 ASIA PACIFIC: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 247 TABLE 305 ASIA PACIFIC: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 247 TABLE 306 ASIA PACIFIC: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 247 TABLE 307 ASIA PACIFIC: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021–2023 (THOUSAND UNITS) 248 TABLE 308 ASIA PACIFIC: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024–2029 (THOUSAND UNITS) 248 TABLE 309 ASIA PACIFIC: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2021–2023 (USD MILLION) 248 TABLE 310 ASIA PACIFIC: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024–2029 (USD MILLION) 249 TABLE 311 ASIA PACIFIC: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 249 TABLE 312 ASIA PACIFIC: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 249 TABLE 313 ASIA PACIFIC: ARRHYTHMIAS MARKET, BY INDICATION, 2021–2023 (USD MILLION) 250 TABLE 314 ASIA PACIFIC: ARRHYTHMIAS MARKET, BY INDICATION, 2024–2029 (USD MILLION) 250 TABLE 315 ASIA PACIFIC: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 250 TABLE 316 ASIA PACIFIC: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 251 TABLE 317 ASIA PACIFIC: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 251 TABLE 318 ASIA PACIFIC: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 251 TABLE 319 ASIA PACIFIC: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2021–2023 (USD MILLION) 252 TABLE 320 ASIA PACIFIC: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024–2029 (USD MILLION) 252 TABLE 321 LATIN AMERICA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2021–2023 (USD MILLION) 253 TABLE 322 LATIN AMERICA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024–2029 (USD MILLION) 254 TABLE 323 LATIN AMERICA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 254 TABLE 324 LATIN AMERICA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 255 TABLE 325 LATIN AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 255 TABLE 326 LATIN AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 255 TABLE 327 LATIN AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021–2023 (THOUSAND UNITS) 256 TABLE 328 LATIN AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024–2029 (THOUSAND UNITS) 256 TABLE 329 LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 256 TABLE 330 LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 257 TABLE 331 LATIN AMERICA: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 257 TABLE 332 LATIN AMERICA: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 258 TABLE 333 LATIN AMERICA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 258 TABLE 334 LATIN AMERICA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 258 TABLE 335 LATIN AMERICA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 259 TABLE 336 LATIN AMERICA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 259 TABLE 337 LATIN AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 259 TABLE 338 LATIN AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 260 TABLE 339 LATIN AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021–2023 (THOUSAND UNITS) 260 TABLE 340 LATIN AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024–2029 (THOUSAND UNITS) 260 TABLE 341 LATIN AMERICA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2021–2023 (USD MILLION) 261 TABLE 342 LATIN AMERICA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024–2029 (USD MILLION) 261 TABLE 343 LATIN AMERICA: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 262 TABLE 344 LATIN AMERICA: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 262 TABLE 345 LATIN AMERICA: ARRHYTHMIAS MARKET, BY INDICATION, 2021–2023 (USD MILLION) 262 TABLE 346 LATIN AMERICA: ARRHYTHMIAS MARKET, BY INDICATION, 2024–2029 (USD MILLION) 263 TABLE 347 LATIN AMERICA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 263 TABLE 348 LATIN AMERICA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 263 TABLE 349 LATIN AMERICA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 264 TABLE 350 LATIN AMERICA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 264 TABLE 351 LATIN AMERICA: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2021–2023 (USD MILLION) 264 TABLE 352 LATIN AMERICA: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024–2029 (USD MILLION) 265 TABLE 353 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2021–2023 (USD MILLION) 266 TABLE 354 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024–2029 (USD MILLION) 266 TABLE 355 MIDDLE EAST & AFRICA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 267 TABLE 356 MIDDLE EAST & AFRICA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 267 TABLE 357 MIDDLE EAST & AFRICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 268 TABLE 358 MIDDLE EAST & AFRICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 268 TABLE 359 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY CARDIAC RHYTHM MANAGEMENT DEVICES, 2021–2023 (THOUSAND UNITS) 268 TABLE 360 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY CARDIAC RHYTHM MANAGEMENT DEVICES, 2024–2029 (THOUSAND UNITS) 269 TABLE 361 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 269 TABLE 362 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 270 TABLE 363 MIDDLE EAST & AFRICA: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 270 TABLE 364 MIDDLE EAST & AFRICA: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 271 TABLE 365 MIDDLE EAST & AFRICA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 271 TABLE 366 MIDDLE EAST & AFRICA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 271 TABLE 367 MIDDLE EAST & AFRICA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 272 TABLE 368 MIDDLE EAST & AFRICA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 272 TABLE 369 MIDDLE EAST & AFRICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 272 TABLE 370 MIDDLE EAST & AFRICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 273 TABLE 371 MIDDLE EAST & AFRICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021–2023 (THOUSAND UNITS) 273 TABLE 372 MIDDLE EAST & AFRICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024–2029 (THOUSAND UNITS) 273 TABLE 373 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2021–2023 (USD MILLION) 274 TABLE 374 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024–2029 (USD MILLION) 274 TABLE 375 MIDDLE EAST & AFRICA: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 275 TABLE 376 MIDDLE EAST & AFRICA: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 275 TABLE 377 MIDDLE EAST & AFRICA: ARRHYTHMIAS MARKET, BY INDICATION, 2021–2023 (USD MILLION) 276 TABLE 378 MIDDLE EAST & AFRICA: ARRHYTHMIAS MARKET, BY INDICATION, 2024–2029 (USD MILLION) 276 TABLE 379 MIDDLE EAST & AFRICA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 276 TABLE 380 MIDDLE EAST & AFRICA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 277 TABLE 381 MIDDLE EAST & AFRICA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 277 TABLE 382 MIDDLE EAST & AFRICA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 277 TABLE 383 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2021–2023 (USD MILLION) 278 TABLE 384 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024–2029 (USD MILLION) 278 TABLE 385 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES 280 TABLE 386 CARDIOVASCULAR DEVICES MARKET: DEGREE OF COMPETITION 284 TABLE 387 CARDIOVASCULAR DEVICES MARKET: REGION FOOTPRINT 288 TABLE 388 CARDIOVASCULAR MARKET: PRODUCT FOOTPRINT 289 TABLE 389 CARDIOVASCULAR DEVICES MARKET: INDICATION FOOTPRINT 290 TABLE 390 CARDIOVASCULAR DEVICES MARKET: END-USER FOOTPRINT 291 TABLE 391 CARDIOVASCULAR DEVICES MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 294 TABLE 392 CARDIOVASCULAR DEVICES MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION 295 TABLE 393 CARDIOVASCULAR DEVICES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024 297 TABLE 394 CARDIOVASCULAR DEVICES MARKET: DEALS, JANUARY 2021–NOVEMBER 2024 298 TABLE 395 CARDIOVASCULAR DEVICES MARKET: EXPANSIONS, JANUARY 2021–NOVEMBER 2024 299 TABLE 396 CARDIOVASCULAR DEVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024 299 TABLE 397 MEDTRONIC: COMPANY OVERVIEW 300 TABLE 398 MEDTRONIC: PRODUCTS OFFERED 301 TABLE 399 MEDTRONIC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024 309 TABLE 400 MEDTRONIC: DEALS, JANUARY 2021–NOVEMBER 2024 310 TABLE 401 ABBOTT LABORATORIES: COMPANY OVERVIEW 312 TABLE 402 ABBOTT LABORATORIES: PRODUCTS OFFERED 313 TABLE 403 ABBOTT LABORATORIES: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024 321 TABLE 404 ABBOTT LABORATORIES: DEALS, JANUARY 2021–NOVEMBER 2024 323 TABLE 405 BOSTON SCIENTIFIC CORPORATION.: COMPANY OVERVIEW 325 TABLE 406 BOSTON SCIENTIFIC CORPORATION.: PRODUCTS OFFERED 326 TABLE 407 BOSTON SCIENTIFIC CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024 333 TABLE 408 BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2021–NOVEMBER 2024 333 TABLE 409 GE HEALTHCARE: COMPANY OVERVIEW 336 TABLE 410 GE HEALTHCARE: PRODUCTS OFFERED 337 TABLE 411 GE HEALTHCARE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024 339 TABLE 412 GE HEALTHCARE: DEALS, JANUARY 2021–NOVEMBER 2024 340 TABLE 413 TERUMO CORPORATION: COMPANY OVERVIEW 342 TABLE 414 TERUMO CORPORATION: PRODUCTS OFFERED 343 TABLE 415 TERUMO CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024 347 TABLE 416 EDWARDS LIFESCIENCES CORPORATION: COMPANY OVERVIEW 349 TABLE 417 EDWARDS LIFESCIENCES CORPORATION: PRODUCTS OFFERED 350 TABLE 418 EDWARDS LIFESCIENCES CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024 352 TABLE 419 EDWARD LIFESCIENCES CORPORATION: DEALS, JANUARY 2021–NOVEMBER 2024 353 TABLE 420 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 354 TABLE 421 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 355 TABLE 422 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024 357 TABLE 423 JOHNSON AND JOHNSON SERVICES, INC.: COMPANY OVERVIEW 358 TABLE 424 JOHNSON AND JOHNSON SERVICES, INC.: PRODUCTS OFFERED 359 TABLE 425 JOHNSON AND JOHNSON SERVICES INC: PRODUCT LAUNCHES & APPROVALS, JANUARY 20210–NOVEMBER 2024 362 TABLE 426 JOHNSON AND JOHNSON SERVICES, INC: DEALS, JANUARY 2021–NOVEMBER 2024 363 TABLE 427 SAHAJANAND MEDICAL TECHNOLOGIES LIMITED: COMPANY OVERVIEW 364 TABLE 428 SAHAJANAND MEDICAL TECHNOLOGIES LIMITED: PRODUCTS OFFERED 364 TABLE 429 BAXTER INTENATIONAL, INC.: COMPANY OVERVIEW 366 TABLE 430 BAXTER INTERNATIONAL, INC.: PRODUCTS OFFERED 367 TABLE 431 BAXTER INTERNATIONAL INC.: DEALS, JANUARY 2021–NOVEMBER 2024 369 TABLE 432 ARTIVION, INC.: COMPANY OVERVIEW 370 TABLE 433 ARTIVION, INC.: PRODUCTS OFFERED 371 TABLE 434 GETINGE AB: COMPANY OVERVIEW 373 TABLE 435 GETINGE AB: PRODUCTS OFFERED 374 TABLE 436 GETINGE AB: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024 375 TABLE 437 GETINGE AB: DEALS, JANUARY 2021–MARCH 2024 375 TABLE 438 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 376 TABLE 439 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED 377 TABLE 440 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024 379 TABLE 441 NIHON KOHDEN CORPORATION: COMPANY OVERVIEW 380 TABLE 442 NIHON KOHDEN CORPORATION: PRODUCTS OFFERED 381 TABLE 443 BIOTRONIK SE & CO.KG.: COMPANY OVERVIEW 383 TABLE 444 BIOTRONIK SE & CO.KG: PRODUCTS OFFERED 383 TABLE 445 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.: COMPANY OVERVIEW 388 TABLE 446 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.: PRODUCTS OFFERED 388 TABLE 447 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.:: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024 394 TABLE 448 MICROPORT SCIENTIFIC CORPORATION: COMPANY OVERVIEW 396 TABLE 449 MICROPORT SCIENTIFIC CORPORATION: PRODUCTS OFFERED 397 TABLE 450 MICROPORT SCIENTIFIC CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024 401 TABLE 451 ANGIODYNAMICS INC.: COMPANY OVERVIEW 403 TABLE 452 ANGIODYNAMICS INC.: PRODUCTS OFFERED 405 TABLE 453 JAPAN LIFELINE CO., LTD.: COMPANY OVERVIEW 406 TABLE 454 JAPAN LIFELINE CO., LTD.PRODUCTS OFFERED 407 TABLE 455 JAPAN LIFELINE CO., LTD: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024 410 TABLE 456 W.L. GORE & ASSOCIATES: COMPANY OVERVIEW 411 TABLE 457 W.L. GORE & ASSOCIATES: PRODUCTS OFFERED 411 TABLE 458 B. BRAUN SE: COMPANY OVERVIEW 412 TABLE 459 B. BRAUN SE.: PRODUCTS OFFERED 414 FIGURE 1 MARKETS & REGIONS COVERED 35 FIGURE 2 RESEARCH DESIGN 38 FIGURE 3 PRIMARY SOURCES 41 FIGURE 4 PRIMARY BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 43 FIGURE 5 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS 44 FIGURE 6 TOP-DOWN APPROACH 44 FIGURE 7 IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2029) 46 FIGURE 8 CARDIOVASCULAR DEVICES MARKET: CAGR PROJECTIONS 47 FIGURE 9 DATA TRIANGULATION METHODOLOGY 48 FIGURE 10 CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION) 51 FIGURE 11 CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 52 FIGURE 12 CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION) 52 FIGURE 13 CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 53 FIGURE 14 GEOGRAPHIC SNAPSHOT OF CARDIOVASCULAR DEVICES MARKET 54 FIGURE 15 INCREASING PREVALENCE OF CARDIOVASCULAR DISEASES TO PROPEL MARKET 55 FIGURE 16 HOSPITALS & CLINICS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 56 FIGURE 17 ASIA PACIFIC TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 57 FIGURE 18 CARDIOVASCULAR DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 58 FIGURE 19 LEADING TRENDS 64 FIGURE 20 CARDIOVASCULAR DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 71 FIGURE 21 NUMBER OF PATENTS PUBLISHED (JANUARY 2014─SEPTEMBER 2024) 77 FIGURE 22 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR CARDIOVASCULAR DEVICES PATENTS (JANUARY 2014−SEPTEMBER 2024) 78 FIGURE 23 TOP APPLICANT COUNTRIES/REGIONS FOR CARDIOVASCULAR DEVICES (JANUARY 2014− JULY 2024) 78 FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CARDIOVASCULAR DEVICES 83 FIGURE 25 KEY BUYING CRITERIA FOR TOP 3 END USERS OF CARDIOVASCULAR DEVICES 84 FIGURE 26 CARDIOVASCULAR DEVICES MARKET: ECOSYSTEM ANALYSIS 87 FIGURE 27 CARDIOVASCULAR DEVICES MARKET: SUPPLY CHAIN ANALYSIS 91 FIGURE 28 REVENUE SHIFT FOR CARDIOVASCULAR DEVICES MARKET 93 FIGURE 29 CARDIOVASCULAR DEVICES MARKET: INVESTMENT & FUNDING SCENARIO (2018–2022) 94 FIGURE 30 CARDIOVASCULAR DEVICES MARKET: GEOGRAPHIC SNAPSHOT 190 FIGURE 31 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET SNAPSHOT 192 FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS IN CARDIOVASCULAR DEVICES MARKET (2021–2023) 282 FIGURE 33 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CARDIOVASCULAR DEVICES MARKET (2023) 283 FIGURE 34 RANKING OF KEY PLAYERS IN CARDIOVASCULAR DEVICES MARKET, 2023 285 FIGURE 35 CARDIOVASCULAR DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 286 FIGURE 36 CARDIOVASCULAR DEVICES MARKET: COMPANY FOOTPRINT 287 FIGURE 37 CARDIOVASCULAR DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 293 FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 295 FIGURE 39 EV/EBITDA OF KEY VENDORS 296 FIGURE 40 CARDIOVASCULAR DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 296 FIGURE 41 MEDTRONIC: COMPANY SNAPSHOT (2024) 301 FIGURE 42 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2023) 313 FIGURE 43 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023) 326 FIGURE 44 GE HEALTHCARE: COMPANY SNAPSHOT (2023) 337 FIGURE 45 TERUMO CORPORATION: COMPANY SNAPSHOT (2023) 343 FIGURE 46 EDWARDS LIFESCIENCES CORPORATION: COMPANY SNAPSHOT (2023) 350 FIGURE 47 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023) 355 FIGURE 48 JOHNSON AND JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2023) 359 FIGURE 49 BAXTER INTENATIONAL, INC.: COMPANY SNAPSHOT (2023) 367 FIGURE 50 ARTIVION, INC.: COMPANY SNAPSHOT (2023) 371 FIGURE 51 GETINGE AB: COMPANY SNAPSHOT (2023) 374 FIGURE 52 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023) 377 FIGURE 53 NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT (2023) 381 FIGURE 54 MICROPORT SCIENTIFIC CORPORATION.: COMPANY SNAPSHOT (2023) 397 FIGURE 55 ANGIODYNAMICS INC.: COMPANY SNAPSHOT (2023) 404 FIGURE 56 JAPAN LIFELINE CO., LTD.: COMPANY SNAPSHOT (2023) 407 FIGURE 57 B. BRAUN SE: COMPANY SNAPSHOT (2023) 413